Cite
Arai H, Elliott A, Millstein J, et al. Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. Oncogene. 2021;41(2):260-267doi: 10.1038/s41388-021-02074-z.
Arai, H., Elliott, A., Millstein, J., Xiu, J., Ou, F. S., Innocenti, F., Wang, J., Battaglin, F., Jayachandran, P., Kawanishi, N., Soni, S., Zhang, W., Sohal, D., Goldberg, R. M., Hall, M. J., Scott, A. J., Khushman, M., Hwang, J. J., Lou, E., Weinberg, B. A., Lockhart, A. C., Shields, A. F., Abraham, J. P., Magee, D., Stafford, P., Zhang, J., Venook, A. P., Korn, W. M., & Lenz, H. J. (2022). Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. Oncogene, 41(2), 260-267. https://doi.org/10.1038/s41388-021-02074-z
Arai, Hiroyuki, et al. "Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer." Oncogene vol. 41,2 (2022): 260-267. doi: https://doi.org/10.1038/s41388-021-02074-z
Arai H, Elliott A, Millstein J, Xiu J, Ou FS, Innocenti F, Wang J, Battaglin F, Jayachandran P, Kawanishi N, Soni S, Zhang W, Sohal D, Goldberg RM, Hall MJ, Scott AJ, Khushman M, Hwang JJ, Lou E, Weinberg BA, Lockhart AC, Shields AF, Abraham JP, Magee D, Stafford P, Zhang J, Venook AP, Korn WM, Lenz HJ. Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. Oncogene. 2022 Jan;41(2):260-267. doi: 10.1038/s41388-021-02074-z. Epub 2021 Nov 02. PMID: 34728807.
Copy
Download .nbib